NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis $2.31 +0.06 (+2.67%) (As of 03:37 PM ET) Add Compare Share Share Today's Range$2.16▼$2.3450-Day Range$1.92▼$2.4052-Week Range$0.96▼$3.77Volume13,040 shsAverage Volume48,726 shsMarket Capitalization$128.39 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cellectis alerts: Email Address Cellectis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside257.1% Upside$8.00 Price TargetShort InterestHealthy0.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.54) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector479th out of 927 stocksBiological Products, Except Diagnostic Industry75th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectis has received no research coverage in the past 90 days.Read more about Cellectis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.69% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Cellectis has recently decreased by 3.29%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLLS. Previous Next 2.0 News and Social Media Coverage News SentimentCellectis has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cellectis this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for CLLS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cellectis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectis are expected to grow in the coming year, from ($0.54) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cellectis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About Cellectis Stock (NASDAQ:CLLS)Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More CLLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLLS Stock News HeadlinesSeptember 10, 2024 | americanbankingnews.comCellectis (NASDAQ:CLLS) Now Covered by StockNews.comSeptember 3, 2024 | globenewswire.comCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving SafetySeptember 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…September 2, 2024 | uk.finance.yahoo.comCellectis S.A. (0WA2.IL)August 30, 2024 | seekingalpha.comCellectis: Cheap With Promising But Speculative Cancer TherapiesAugust 28, 2024 | uk.finance.yahoo.comCellectis SA (ZVAA.DU)August 26, 2024 | globenewswire.comCellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid TumorsAugust 10, 2024 | markets.businessinsider.comCellectis SA: Strong Buy Rating on Robust Pipeline and Financial StabilitySeptember 16, 2024 | Crypto 101 Media (Ad)Trillion Dollar Blockchain Shift Could Trigger THIS CoinIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…August 8, 2024 | msn.comCellectis Non-GAAP EPS of -$0.22 beats by $0.09, revenue of $9.5M misses by $0.2MAugust 7, 2024 | globenewswire.comCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical OfficerAugust 7, 2024 | markets.businessinsider.comCLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | msn.comCellectis GAAP EPS of -$0.28 beats by $0.02, revenue of $9.5M beats by $5.77MAugust 6, 2024 | globenewswire.comCellectis Provides Financial Results for the Second Quarter 2024August 3, 2024 | stockhouse.comFDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 2, 2024 | finanznachrichten.deCellectis Inc.: FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL TreatmentAugust 2, 2024 | marketwatch.comCellectis Gets Orphan Designation for Drug Used in Cancer TreatmentAugust 1, 2024 | finance.yahoo.comFDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL TreatmentSee More Headlines Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/16/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees290Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+257.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,060,000.00 Net Margins-401.83% Pretax Margin-403.58% Return on Equity-78.90% Return on Assets-24.17% Debt Debt-to-Equity Ratio0.39 Current Ratio1.92 Quick Ratio1.92 Sales & Book Value Annual Sales$9.19 million Price / Sales13.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.52 per share Price / Book1.47Miscellaneous Outstanding Shares55,580,000Free Float46,463,000Market Cap$124.50 million OptionableOptionable Beta3.09 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Andre Choulika Ph.D. (Age 59)Co-Founder, CEO & Director Comp: $744.02kDr. David j. d. Sourdive Ph.D. (Age 57)Deputy CEO, Executive VP of CMC & Manufacturing and Director Comp: $528.92kDr. Bing C. Wang M.B.A. (Age 47)Ph.D., Chief Financial Officer Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerMr. Jean Charles EpinatChief Technological OfficerDr. Philippe Duchateau Ph.D. (Age 61)Chief Scientific Officer Mr. Stephan Reynier M.Sc. (Age 55)Chief Regulatory & Pharmaceutical Compliance Officer Ms. Marie-Bleuenn Terrier (Age 42)General Counsel & Secretary of the Board of Directors Pascalyne WilsonDirector of CommunicationsMs. Kyung Nam-Wortman (Age 54)Executive VP & Chief Human Resources Officer More ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTNeurogeneNASDAQ:NGNEAcelyrinNASDAQ:SLRNOculisNASDAQ:OCSKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInstitutional OwnershipLong Focus Capital Management LLCBought 130,000 shares on 8/15/2024Ownership: 8.307%XTX Topco LtdBought 15,320 shares on 8/12/2024Ownership: 0.028%Principal Financial Group Inc.Bought 12,467 shares on 7/29/2024Ownership: 0.786%Baillie Gifford & Co.Sold 119,618 shares on 7/25/2024Ownership: 1.273%View All Institutional Transactions CLLS Stock Analysis - Frequently Asked Questions How have CLLS shares performed this year? Cellectis' stock was trading at $3.08 on January 1st, 2024. Since then, CLLS shares have decreased by 27.3% and is now trading at $2.24. View the best growth stocks for 2024 here. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. The biotechnology company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $6 million. Cellectis had a negative trailing twelve-month return on equity of 78.90% and a negative net margin of 401.83%. When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Cellectis' major shareholders? Cellectis' top institutional investors include Long Focus Capital Management LLC (8.31%), Baillie Gifford & Co. (1.27%), Principal Financial Group Inc. (0.79%) and XTX Topco Ltd (0.03%). How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD) and CRISPR Therapeutics (CRSP). This page (NASDAQ:CLLS) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
